trial

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

NCTId NCT04030143
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 266 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2020-07-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
266 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2019-08-01
Primary completion
2020-07-08
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

19 total
Little Rock, United StatesRogers, United StatesBellflower, United StatesGarden Grove, United StatesGlendale, United StatesLemon Grove, United StatesOrange, United StatesSan Diego, United StatesTorrance, United StatesHollywood, United StatesMiami Lakes, United StatesAtlanta, United States

Linked catalysts

1
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipola — primary completion2020-07-08

Facts & assertions

4 sourced
Enrollment
266
Phase
PHASE1,PHASE2
Primary Completion Date
2020-07-08
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Bipolar I Disorder
indication